Compare Adaptive Biotechnologies Corp (ADPT) vs Philip Morris International Inc. (PM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Philip Morris International Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Philip Morris International Inc. trades at $187.41 (market cap $287.96B). The key difference: Philip Morris International Inc. is far larger — about 86.5× Adaptive Biotechnologies Corp's market cap, and Philip Morris International Inc. pays a 3.18% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | PM | |
|---|---|---|
Market Cap | $3.33B | $287.96B |
Sector | Health | Consumer Staples |
52-Week High | $22.37 | $191.86 |
52-Week Low | $10.24 | $144.33 |
Enterprise Value | $3.19B | $334.46B |
Dividend Yield | — | 3.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Philip Morris International (PM) trades at $184.76, up 1.37% with strong technical momentum and bullish moving averages. The company reported solid Q1 2026 earnings beat ($1.96 vs $1.86 expected) and maintains robust profitability with 26.74% net income margin. Recent news includes a $500 million impairment charge on Canadian operations and updated 2026 guidance, though IQOS brand recognition remains a positive catalyst.
PM offers stable revenue growth and strong cash flow generation, but faces headwinds from currency volatility and illicit market pressures. Analyst consensus remains bullish with $194.25 price target (68% buy ratings), though recent profit forecast cuts and high debt levels warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
